Immunotherapy for nonsmall-cell lung cancer

Memo - Magazine of European Medical Oncology

Volumn 5, Issue 2, 2012, Pages 90-93

  Belalcazar, Astrid ^b   Raez, Luis E ^a,c   Santos, Edgardo S ^d  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c Memorial Health Care System   (United States)

^d UNIVERSITY OF MIAMI   (United States)

Author keywords

Antigens; BLP25; Immunotherapy; MAGE A3; Nonsmall cell lung cancer; Stimuvax; Vaccines

Indexed keywords

ANGIOGENESIS INHIBITOR; BELAGENPUMETUCEL L; CANCER VACCINE; CISPLATIN; EMEPEPIMUT S; EPIDERMAL GROWTH FACTOR VACCINE; GAMMA INTERFERON; INTERLEUKIN 4; INTERLEUKIN 6; MELANOMA ANTIGEN 3; NAVELBINE; PROTEIN TYROSINE KINASE INHIBITOR; TG 4010; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CYTOKINE PRODUCTION; DISEASE FREE SURVIVAL; DRUG MEGADOSE; ERYTHEMA; HUMAN; IMMUNOMODULATION; INJECTION SITE PAIN; LUNG NON SMALL CELL CANCER; MAINTENANCE CHEMOTHERAPY; METASTASIS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME;

EID: 84866095529     PISSN: 18655041     EISSN: 18655076     Source Type: Journal    
DOI: 10.1007/s12254-012-0019-y     Document Type: Review

References (24)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Rosell R, Skrzypski M, Jassem E, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One. 2007;2(11):e1129.
3. Holt GE, Podack ER, Raez LE. Immunotherapy as a strategy for the treatment of nonsmall cell lung cancer. Therapy. 2011;8(1):43-54.
4. Gross S, Walden P. Immunosuppressive mechanisms in human tumors: Why we still cannot cure cancer? Immunol Lett. 2008;116(1):7-14.
5. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration resistant prostate cancer. N Engl J Med. 2010;363(5):411-22.
6. Kong F, Jirtle RL, Huang DH, et al. Plasma transforming growth factor-β1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer. 1999;86(9):1712-9. (Pubitemid 29513039)
7. Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol. 2006;24(29):4721-30.
8. Clinicaltrials.gov: Phase III Lucanix vaccine therapy in advanced non-small-cell lung cancer (NSCLC) following front-line chemotherapy (STOP). www.clinicaltrials.gov/ct2/show/NCT00676507. Accessed 1 Feb. 2012.
9. Sienel W, Varwerk C, Linder A, et al. Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg. 2004;25(1):131-4. (Pubitemid 38019071)
10. Vansteenkiste J, Zielinski M, Linder A, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II nonsmall cell lung cancer (NSCLC). J Clin Oncol. 2007;s25:7554 (Meeting Abstracts).
11. Clinicaltrials.gov: GSK1572932A antigen-specific cancer immunotherapeutic as adjuvant therapy in patients with non-small-cell lung cancer. www.clinicaltrials.gov/ct2/show/NCT00480025. Accessed 1 Feb. 2012.
12. Raina D, Kosugi M, Ahmad R, et al. Dependence on the MUC1-C oncoprotein in non-small-cell lung cancer cells. Mol. Cancer Ther. 2011;10(5):806-16.
13. Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV nonsmall-cell lung cancer. J Clin Oncol. 2005;23(27):6674-81.
14. Butts C, Maksymiuk A, Goss G, et al. A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis: B1-01. J Thor Oncol. 2007;2(8):s332-3.
15. Butts C, Murray RN, Smith CJ, et al. A multicenter openlabel study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer. Clin Lung Cancer. 2010;11(6):391-5.
16. Clinicaltrials.gov: Cancer vaccine study for unresectable stage III non-small-cell lung cancer. www.clinicaltrials. gov/ct2/show/NCT00409188. Accessed 1 Feb 2012.
17. Rochlitz C, Figlin R, Squiban P, et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med. 2003;5(8):690-9. (Pubitemid 40309707)
18. Ramlau R, Quoix E, Rolski J, et al. A phase II study of Tg4010 (Mva-Muc1-IL2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J Thorac Oncol. 2008;3(7):735-44.
19. Acres B, Quoix E, Ramlau R, et al. Biomarkers associated with clinical outcome in advanced non-small cell lung cancer patients treated with TG4010. J Clin Oncol. 2009;s27:3027 (Meeting Abstracts).
20. Clinicaltrials.gov: Immunotherapy with TG4010 in patients with advanced non-small-cell lung cancer http://clinicaltrials. gov/ct2/show/NCT01383148. Accessed 1 Feb 2012.
21. Rodriguez G, Albisa A, Viña L, et al. Manufacturing process development for an epidermal growth factor-based cancer vaccine. Int Biopharm. 2008;21(10):36-42.
22. Gonzalez G, Crombet T, Catala M, et al. A novel cancer vaccine composed of human recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol. 1998;9(4):431-5. (Pubitemid 28273037)
23. Garcia B, Neninger E, de la Torre A, et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res. 2008;14(3):840-6. (Pubitemid 351231168)
24. Neninger Vinageras E, de la Torre A, Osorio Rodriguez M, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol. 2008;26(9):1452-8.